BeyondSpring to Showcase Plinabulin at Global Conferences
BeyondSpring Inc. (NASDAQ: BYSI), a leading clinical-stage biopharmaceutical company, is thrilled to announce its upcoming oral and poster presentations at notable cancer conferences. A major highlight will be the efficacy data from the Dublin-3 Phase 3 study, which will be presented at the 2024 World Conference on Lung Cancer. This presentation will emphasize the effectiveness of Plinabulin in combination with docetaxel for treating non-small cell lung cancer (NSCLC).
Presentation Highlights at the 2024 World Conference on Lung Cancer
On September 9, 2024, in San Diego, California, an oral presentation titled "Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial" will explore innovative treatment options in the battle against cancer. Dr. Trevor M. Feinstein, the principal investigator for the Dublin-3 study, will lead this important session.
- Presenter: Dr. Trevor M. Feinstein
- Time: September 9, 2024, from 10:57 AM to 11:07 AM PDT
- Session: OA08. The New Generation of Cytotoxics
Posters to Present Additional Research at ESMO Congress 2024
In addition to the oral presentation, BeyondSpring will feature two poster presentations during the European Society for Medical Oncology (ESMO) Congress 2024, taking place on September 14, 2024, in Barcelona, Spain.
Highlighted Poster Presentations
- Poster (1358P): This study will explore the survival benefits of Plinabulin/Docetaxel compared to traditional docetaxel treatment in EGFR wild-type NSCLC patients. The presentation will occur from 9 AM to 6:30 PM CEST.
- Poster (1330P): This presentation will focus on a Phase 2 study assessing Plinabulin in combination with pembrolizumab and docetaxel for metastatic NSCLC patients who are progressing after first-line therapies. Like the other session, this poster will also run from 9 AM to 6:30 PM CEST.
About Plinabulin and Its Development
Plinabulin is a first-in-class treatment developed by BeyondSpring that plays a crucial role in promoting dendritic cell maturation, an essential process for effective cancer therapy. Primarily aimed at non-small cell lung cancer, this promising treatment is currently undergoing extensive clinical trials to evaluate its potential for improving patient outcomes.
BeyondSpring's clinical pipeline also features several preclinical immuno-oncology assets, underscoring the company's commitment to tackling significant medical challenges through innovative therapies.
About the Dublin-3 Study
The Dublin-3 NSCLC study is a pivotal Phase 3 trial that compares the efficacy of Plinabulin combined with docetaxel to docetaxel alone in patients who have not responded to platinum doublet therapies. By evaluating survival rates and progression-free survival, this study aims to support the development of more effective treatment protocols for NSCLC.
About Study 303
At the same time, Study 303 is investigating the effectiveness of Plinabulin when used alongside pembrolizumab and docetaxel for patients experiencing disease progression after previous treatments. Conducted at the Peking Union Medical College Hospital, this research aims to establish a strong safety profile and positive efficacy results for metastatic NSCLC.
Frequently Asked Questions
What is BeyondSpring Inc.?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies that aim to improve clinical outcomes for patients.
What is Plinabulin?
Plinabulin is an anti-cancer agent created by BeyondSpring that promotes dendritic cell maturation, playing a significant role in various cancer treatment strategies.
When will the presentations take place?
The oral presentation is scheduled for September 9, 2024, at the World Conference on Lung Cancer, while the poster presentations will occur on September 14, 2024, at the ESMO Congress.
Who are the presenters for these studies?
Dr. Trevor M. Feinstein will present at the World Conference, and Dr. Yan Xu will take the stage during the ESMO Congress.
How does the Dublin-3 study impact cancer treatment?
The Dublin-3 study aims to assess the effectiveness of combining Plinabulin with existing treatments, potentially leading to improved outcomes for patients with NSCLC.
